SERVICES

How we tackle projects

myNEO Therapeutics offers myNEO intelligence, your go-to partner for immunogenomic, end-to-end services across the different stages of your IO development pipeline. Our expert team closely collaborates with our clients and partners wherein open communication and flexibility is key. We go the extra mile for your project and strive to achieve the highest quality within the set milestones, timeline, and budget.



Definition of work packages



Assembly of expert team



Distribution of workload



Tracking of milestones



Regular communication



Detailed reporting

Target discovery

Early discovery of cancer neo(antigen) targets

E

Screening omics databases and patient biopsies

E

Matching tumor targets with population of interest for optimal coverage

E

Selection of an optimal set of immunogenic epitopes

E

Differential expression analysis and genome-wide association studies

Target selection

E

SNVs & Indels, gene fusions, RTE insertions, neoisoforms,…

E

Other cancer events: TMB, MET exon14 skipping,…

Target prioritization based on proprietary algorithms

E

neoMS: MHC-presentation

E

neoIM: immunogenicity scoring

E

Functional relevance, clonality, immune-escape likelihood

Coordination of biopt sequencing

Set up safe cloud infrastructures

Pre-clinical

Construct design

E

Incorporation of epitope subsets into larger constructs

E

Shuffling epitopes and linkers to optimize the efficacy and safety

Design and coordination of pre-clinical validation experiments

E

Target confirmation in patient biopsies

E

In-vitro immunogenicity assays

E

MS ligandomics

E

In-vitro tumor killing assays

E

Organoid assays

Scientific advice and support of the pre-clinical roadmap

E

KOL support from lead candidate(s) selection to IND studies

E

Support in the selection of manufacturing site for R&D product and GMP product

Mechanism of action (MoA) and pathway analysis

E

Using QIAGEN Ingenuity Pathway Analysis

E

Starting from RNAseq datasets

Clinical

Deep investigation of patient data

E

Omics, TCRseq, ELISpot, ICS, MSD 30-plex, IHC, immunophenotyping, Nanostring, …

E

ctDNA patient monitoring and follow-up

E

Tumor-specific mutational profiling

E

Comparison vs digital genomic twin with similar immuno-genomic profile

Biomarker identification based on clinical trial results

E

Pre-treatment biomarkers for patient stratification

E

Early biomarkers correlating with clinical response

Patient-centric translational data analysis

Therapy response prediction

E

TMB, MSI , immunogenic neoantigen load

E

Tumor heterogeneity, TME classification

E

AI-driven multi-parametric analysis

Experimental design

Set-up of patient data visualization platform

How do we offer services?

E

One-time Only Service Agreement

E

Project scope defined by the client

E

Project proposal with well-defined timelines, costs & deliverables

E

Results delivered via a final report (report format chosen by the client: simple vs interactive report)

E

Final meeting wherein the project results are discussed

E

Long-term Master Service Agreement
(MSA) + monthly work orders

E

Fixed daily fee based on FTE effort & tech access

E

Set-up monthly work orders with predictable timelines, costs, deliverables

E

Fine-tuning/adaptations during the project are possible

E

Meetings with the client on weekly basis

Innovating immunotherapies,
transforming tomorrow

Subscribe to our newsletter

Get the latest news & updates about myNEO Therapeutics

Home

About us

Products

Technology

Partners

Services

Contact

Quick links

Publications